Results 121 to 130 of about 1,100,787 (194)

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. [PDF]

Br J Clin Pharmacol
Kumagai Y, Fujita T, Maeda M, Yamamoto A, Amano H.   +4 more
europepmc   +1 more source

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor. [PDF]

Kidney Int Rep, 2021
Nie G, Sun L, Sun B, Zhu H, Li J, Xing C, Zhang B.   +6 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review. [PDF]

J Clin Exp Hematop
Ito K, Hirano K, Sekiguchi N.
europepmc   +1 more source

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2021
Weber MS, Nicholas JA, Yeaman MR.
europepmc   +1 more source

A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor. [PDF]

Br J Haematol
Heß G, Eyre TA, Jen MH, Zhang J, Goebel B, Abhyankar S, Dreyling M.   +6 more
europepmc   +1 more source

Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy. [PDF]

J Hematol
Dalmazzo M, Padrini M, Camerlo S, Rosati G, Busana TT, Nicoli P, Perotto F, Davicco L, Caironi P, De Gobbi M, Morotti A.   +10 more
europepmc   +1 more source

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. [PDF]

Blood, 2021
Pleyer C, Ali MA, Cohen JI, Tian X, Soto S, Ahn IE, Gaglione EM, Nierman P, Marti GE, Hesdorffer C, Lotter J, Superata J, Wiestner A, Sun C.   +13 more
europepmc   +1 more source

Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. [PDF]

Oncologist
Fernandez Turizo MJ, Kim E, Zhang C, Yankama T, Von Keudell G, Sermer DJ, Mejías-De Jesús C, Asnani A.   +7 more
europepmc   +1 more source

A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. [PDF]

Br J Haematol, 2022
Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J.   +15 more
europepmc   +1 more source

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. [PDF]

Haematologica
Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR.   +34 more
europepmc   +1 more source